Human trial for gene therapy. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Human trial for gene therapy. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Treat Issues. 1995 Jan;9(1):9. Unique Identifier : AIDSLINE AIDS/95700117
Chang HE

Abstract: Scientists will undertake the first clinical study using gene therapy against HIV by giving cells the gene for a double ribozyme, which cleaves HIV's genetic RNA material at two distinct sites. The double ribozyme has exhibited more potent anti-HIV effects in cell cultures than the single ribozyme, the U5 hairpin, used in previous studies and may be less vulnerable to resistance. In phase I of the proposed study, white blood cells will be removed from six HIV-infected volunteers on AZT therapy with CD4 counts greater than 250. CD4 cells will be selected out, proliferated, and infected with a harmless virus shell containing the gene for the double ribozyme. Cells will be infused back into the body and tracked for number and longevity.

Keywords: *Gene Therapy Human HIV/PHYSIOLOGY HIV Infections/GENETICS/*THERAPY RNA, Catalytic/*GENETICS NEWSLETTER ARTICLE
950530
M9551022

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .